- Home
- NG vs NEO Comparison
NG vs NEO Comparison
Compare NG & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NG | NEO |
|---|---|---|
| Founded | 1984 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Precision Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | NG | NEO |
|---|---|---|
| Price | $9.98 | $12.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $10.17 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 2.5M | 1.6M |
| Earning Date | 01-22-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,162,000.00 |
| Revenue This Year | N/A | $10.87 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $2.26 | $4.72 |
| 52 Week High | $10.90 | $19.12 |
Technical Indicators
Market Signals| Indicator | NG | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.62 | 68.36 |
| Support Level | $8.92 | $11.42 |
| Resistance Level | $10.10 | $12.42 |
| Average True Range (ATR) | 0.40 | 0.44 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 70.41 | 94.80 |
Price Performance
Historical ComparisonAbout NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.